Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its ...

Monoclonal antibodies (Mabs) conjugated to toxins or ... we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient ...

The following antibodies were used for phenotyping and proliferation assays: anti-CD3-PE/Cy7 (clone SK7, BioLegend, San Diego, CA), anti-CD4-PerCP (clone SK3, BD Pharmigen, San Jose, CA), anti-CD4 ...

We will cover first clinical results of applying anti-CD19 and anti-B cell maturation antigen CAR T cells for B cell elimination ... 1 Additionally, detrimental immune cells can be more specifically ...

4 Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany Objectives CD19-targeting chimeric ...